The 60-year evolution of lipid nanoparticles for nucleic acid delivery.

Autor: Cullis PR; Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada. pieterc@mail.ubc.ca., Felgner PL; Department of Physiology & Biophysics, University of California, Irvine, CA, USA. pfelgner@hs.uci.edu.
Jazyk: angličtina
Zdroj: Nature reviews. Drug discovery [Nat Rev Drug Discov] 2024 Sep; Vol. 23 (9), pp. 709-722. Date of Electronic Publication: 2024 Jul 04.
DOI: 10.1038/s41573-024-00977-6
Abstrakt: Delivery of genetic information to the interior of target cells in vivo has been a major challenge facing gene therapies. This barrier is now being overcome, owing in part to dramatic advances made by lipid-based systems that have led to lipid nanoparticles (LNPs) that enable delivery of nucleic acid-based vaccines and therapeutics. Examples include the clinically approved COVID-19 LNP mRNA vaccines and Onpattro (patisiran), an LNP small interfering RNA therapeutic to treat transthyretin-induced amyloidosis (hATTR). In addition, a host of promising LNP-enabled vaccines and gene therapies are in clinical development. Here, we trace this success to two streams of research conducted over the past 60 years: the discovery of the transfection properties of lipoplexes composed of positively charged cationic lipids complexed with nucleic acid cargos and the development of lipid nanoparticles using ionizable cationic lipids. The fundamental insights gained from these two streams of research offer potential delivery solutions for most forms of gene therapies.
(© 2024. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: